The 2 or 4‑week subcutaneous therapy with the recently approved antibodies 
alirocumab and evolocumab for inhibition of proprotein convertase 
subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol 
(LDL-C) in addition to statins and ezetimibe by 50-60 %. The therapy is 
well-tolerated. The safety profile in the published studies is comparable to 
placebo. Outcome data and information on long-term safety and the influence on 
cardiovascular events are not yet available but the results of several large 
trials are expected in 2016-2018. At present (spring 2016) PCSK9 inhibitors 
represent an option for selected patients with a high cardiovascular risk and 
high LDL-C despite treatment with the maximum tolerated oral lipid-lowering 
therapy. This group includes selected patients with familial 
hypercholesterolemia and high-risk individuals with statin-associated muscle 
symptoms (SAMS).